跳至主要内容
临床试验/NL-OMON54182
NL-OMON54182尚未招募3 期

Sodium-oxybate as a potential new treatment for catatonia in patients with depression, bipolar disorder or a psychotic disorder, a randomized controlled trial. The Laborit study. - Laborit study

Amsterdam UMC0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -Patients (age 18-80) with catatonia
  • -With DSM-5 diagnosis of either unipolar depression, bipolar disorder, or a
  • psychotic disorder admitted to an acute psychiatric ward.
  • -No response to usual care, with increasing doses of lorazepam to a maximum of
  • 24 mg during 4 days.
  • -Presence of catatonia will be assessed using the BFCTRS(15). Catatonia is
  • considered present with a score of two or higher on the BFCTRS.
  • -Catatonia is present for a maximum of eight weeks.

排除标准

  • -Somatic disorder underlying catatonia.
  • -Use of anti-psychotic drugs.
  • -Known heart failure or renal impairment due to signifcant amounts of sodium in
  • the sodium-oxybate.
  • -Known sleep apnea.
  • -Use of Gabaergic drugs including gabapentin or pregabalin or clonidine. Or us
  • of valproate.
  • -Presence of alcohol use disorder
  • -Presence of malignant catatonia or development of catatonia during the study,
  • i.e. those with malignant catatonia will be treated immediately with ECT

研究者

发起方
Amsterdam UMC

相似试验